#### Check for updates

#### **OPEN ACCESS**

EDITED BY Atalel Fentahun Awedew, Addis Ababa University, Ethiopia

REVIEWED BY François Dépret, Assistance Publique Hopitaux De Paris, France Yasuhiro Tsubosa, Shizuoka Cancer Center, Japan

\*CORRESPONDENCE Shinji Mine S.mine.gv@juntendo.ac.jp

SPECIALTY SECTION

This article was submitted to Visceral Surgery, a section of the journal Frontiers in Surgery

RECEIVED 13 February 2023 ACCEPTED 27 March 2023 PUBLISHED 21 April 2023

#### CITATION

Wang Q, Mine S, Nasu M, Fukunaga T, Nojiri S and Zhang C-D (2023) Association of hospital volume and long-term survival after esophagectomy: A systematic review and meta-analysis. Front. Surg. 10:1161938.

doi: 10.3389/fsurg.2023.1161938

#### COPYRIGHT

© 2023 Wang, Mine, Nasu, Fukunaga, Nojiri and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these

terms.

# Association of hospital volume and long-term survival after esophagectomy: A systematic review and meta-analysis

Qing Wang<sup>1,2</sup>, Shinji Mine<sup>1\*</sup>, Motomi Nasu<sup>1</sup>, Tetsu Fukunaga<sup>1</sup>, Shuko Nojiri<sup>3</sup> and Chun-Dong Zhang<sup>4</sup>

<sup>1</sup>Department of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan, <sup>2</sup>Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China, <sup>3</sup>Medical Technology Innovation Center, Juntendo University, Tokyo, Japan, <sup>4</sup>Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

**Background:** It remains controversial whether esophageal cancer patients may benefit from esophagectomy in specialized high-volume hospitals. Here, the effect of hospital volume on overall survival (OS) of esophageal cancer patients post esophagectomy was assessed.

**Methods:** PubMed, Embase, and Cochrane Library were systematically searched for relevant published articles between January 1990 and May 2022. The primary outcome was OS after esophagectomy in high- vs. low-volume hospitals. Random effect models were applied for all meta-analyses. Subgroup analysis were performed based on volume grouping, sample size, study country, year of publication, follow-up or study quality. Sensitivity analyses were conducted using the leave-one-out method. The Newcastle-Ottawa Scale was used to assess the study quality. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidance, and was registered (identifier: INPLASY202270023).

**Results:** A total of twenty-four studies with 113,014 patients were finally included in the meta-analysis. A significant improvement in OS after esophagectomy was observed in high-volume hospitals as compared to that in their low-volume counterparts (HR: 0.77; 95% CI: 0.71–0.84, P < 0.01). Next, we conducted subgroup analysis based on volume grouping category, consistent results were found that high-volume hospitals significantly improved OS after esophagectomy than their low-volume counterparts. Subgroup analysis and sensitivity analyses further confirmed that all the results were robust.

Conclusions: Esophageal cancer should be centralized in high-volume hospitals.

KEYWORDS

esophageal carcinoma, esophagectomy, hospital volume, overall survival, centralization

# 1. Introduction

Centralization of demanding cancer surgeries to improve the safety and effectiveness of cancer treatment is a topic of ongoing concern in many countries around the world (1-4). Esophagectomy is one of the most complex surgery with high morbidity and mortality, and whether it should be centralized in high-volume hospitals remains controversial (5-9).

Abbreviations

CI, confidence interval; HR, hazard ratio; HV, hospital volume; HVH, high-volume hospital; LVH, low-volume hospital; No., number; NR, not reported; ref, reference; USA, United States of America.

Clinical long-term outcomes of esophageal cancer after surgery are usually affected by standardization of surgical procedures, chemotherapy, radiation therapy, molecular targeted therapy and immunotherapy (10–12); moreover, hospital volume also influences mortality after esophagectomy (13). Some previous studies have been reported that esophagectomy for cancer centralized in high-volume hospitals benefited long-term prognosis outcomes (6, 7, 14, 15), whereas, there are also some reports showing inconsistent results (5, 8, 9, 16). Therefore, whether a better long-term overall survival after esophagectomy showing high-volume hospitals remains to be established.

In the present study, we evaluated the influence of high- vs. low-volume hospitals on the long-term OS of patients with esophageal cancer after esophagectomy.

## 2. Materials and methods

#### 2.1. Literature search strategy

This systematic review was registered in https://doi.org/10. 37766/inplasy2022.7.0023 (identifier: INPLASY202270023) (17). We conducted a systematic search for all relevant articles on the relationship between hospital volume of esophagectomies and long-term OS (17). The search was performed in PubMed, Embase, and Cochrane Library. For example, we combined Medical Subject Headings (MeSH) terms and text terms for the search in PubMed. The following search terms were used: ("esophagectomy" OR "esophageal surgery " OR "esophageal cancer surgery" OR "esophageal resection" OR "esophageal cancer resection") AND ("hospital volume" OR "high volume" OR "low volume" OR "healthcare institution size" OR "surgical volume"). We also searched the references of the included studies to search for potentially eligible articles. The last search was completed on May 30, 2022. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidance (PRISMA) (17, 18).

#### 2.2. Study selection and eligibility criteria

As we previously described, after the retrieval of the relevant articles, they were screened to remove the duplicates (17). All studies were published in English. Search results were screened by two authors (Q.W. and C.D.Z.) independently according to the titles and abstracts. To better reflect modern surgical practices and perioperative management, this study focuses only on articles published after 2002. Next, the retained studies were searched for their full text and further were screened according to the following eligibility criteria: publication in English language; surgery for esophageal carcinoma as the theme; primary outcomes included hospital volume and long-term OS; comparison of OS between high- and low-volume hospitals; original articles with informative data; articles reporting adjusted hazard ratios (HRs) in multivariate analysis; publication before 2002; and articles in which procedural volume was an exact cutoff. Any disagreements were resolved through consultation with the third author (17).

#### 2.3. Data extraction

Two authors (QW and CDZ) independently extracted data from the included studies and collated the following information: author, published year, country, study period, population, the unit of exposure (hospital volume), volume classification for hospitals, volume grouping (dichotomies, tertiles, quartiles, quintiles or others) and the longest follow-up and clinical outcomes (OS) (17). Any disagreements were resolved by discussion with the third author. We further assessed the extent of risk adjustment (17).

#### 2.4. Study quality evaluation

All included studies were rigorously assessed for methodological quality and risk of bias by two authors (QW and CDZ) by using the Newcastle-Ottawa Scale (17, 19). This scale assesses the quality of studies from three aspects: selection of study population (0–4 points), comparability between groups (0–2 points), and outcome measurement (0–3 points) (17). The total score is 9 points.

#### 2.5. Data integration

High-volume hospitals or low-volume hospitals were defined by the authors of the included studies. We used hazard ratios (HRs) in low-volume groups as the reference. If an included study reported more than two surgical volume groups, only the lowest and highest volume groups were compared in the analysis. The primary outcome was OS at the last follow-up, excluding 30-day mortality, 90-day mortality, in-hospital mortality, and postoperative mortality (17).

### 2.6. Statistical analyses

The results were calculated by HRs with 95% confidence intervals (CIs) for long-term outcomes. Heterogeneity among the studies was quantified by the  $I^2$  test, and studies with a statistic of 25%–50% of  $I^2$  were regarded as low heterogeneous, 51%–75% as moderate, and more than 75% as highly heterogeneous (20). Regarding the clinical heterogeneity (inconsistency in pathological staging, therapeutic regimens, and other confounding factors among the studies), we applied randomeffect models for all the analyses. To obtain adequate statistical power, subgroup analysis was conducted based on volume grouping category. Then meta-analyses of at least five included studies were performed for different cutoff values (high-volume hospital vs. low-volume hospital). In addition, subgroup analyses in relation to volume group, sample size, study country, year of publication, follow-up or study quality and sensitivity analyses of a leave-one-out method were conducted to verify the results. Funnel plots were used to evaluate potential publication bias. P < 0.05 was considered to be statistically significant. All statistical analyses were performed by Review Manager 5.4.1 and Stata 13.1.

# 3. Results

## 3.1. Study selection and characteristics

This systematic review was registered in https://doi.org/10. 37766/inplasy2022.7.0023 (identifier: INPLASY202270023). Figure 1 shows the process of literature selection. We retrieved 115 articles from PubMed and 66 from Embase; of these, 136 studies were retained for primary selection after 59 duplicate studies were excluded. After screening of titles and abstracts, 30 studies were excluded. Among the remaining 106 articles, which were related to the volume-outcome relationship in esophageal cancer surgery, we further excluded 24 reviews without primary data, three articles not related to esophagectomy, 23 articles without data of long-term survival, 10 articles without data of hospital volume, three articles without data of low-volume hospitals, four articles published before 2002. Finally, 24 studies published from 2002 to May 2022 with 113,014 participants were included in the meta-analysis.

Among the 24 included studies, six were from the United States (6–8, 21–23), four from Sweden (9, 15, 24, 25), three each from Australia (26–28) and Netherlands (29–31), two each from Japan (32, 33) and England (14, 34), and one each from China (35), Korea (36), Brazil (37), and Canada (38) (Table 1). The longest follow-up period was 24 years.



Aeriod         Aeriod         (6)         Hot         Low         Category         Follow-up year $me$ 2012         Netherands         1995-2006         0.0055         N/R         7.6%         H/V         2:21         5:5         Quantiss         3 yarss $me$ 2013         Netherands         1995-2006         0.055         7.6%         H/V         15:3         Quantiss         3 yarss         3 yarss           2013         Needen         1987-2005         1335         6.600         7.6%         H/V         2:23         Quantiss         1 yarss         5 yarss           2013         Needen         1977-305         1335         6.600         7.40%         H/V         2:26         Quantiss         5 yarss           2013         Needen         1977-305         1335         6.600         7.40%         H/V         2:17         5 warss         5 yarss         5 yarss           2014         1978-3004         17.739         2.640         N/R         N/R         H/V         2:17         5 warss         1 yarss         5 yarss           2014         1978-3         1978-3         17         17         17         17         1 yarss	Author, year	Year	Country	Study	Population	Age, years	Male	Exposure	Hospital volume	ital me	Volume grouping	The longest	Survival	Hospital
2012         Netherlands         1989-2009         10025         NR         76.06         HV         221         55         Quittles         3 years           301         Netherlands         1995-2006         638         66.0         75.56         HV         15-20         -4         Tertiles         3 years           2013         England         2040-2008         5435         66.0         75.56         HV         21-1         0         Quintiles         1 years         0           2013         England         2040-2003         1335         66.0         74.06         HV         21-7         5         Quintiles         5 years           2013         Sweden         1997-2005         1335         66.0         74.06         HV         21-7         5         Quintiles         5 years           2014         1994-1999         11/739         65.0-6.0         18,0         HV         21-7         5         Quintiles         5 years         5           2014         1994-1999         12/246         640-65.0         83.14         HV         21-7         5         2         Quintiles         5 years           2017         1994         1992         1992-1909	[Ref]			Period			(%)		High	Low	Category	Follow-up, year	After	Number
met         1         Netherlands         1995-2006         638         660         75%         HV         15-20         74         Tertiles         3 years           2013         USA         2004-2005         5403         17.9%         HV         21-5         01-10<	Dikken (4)	2012	Netherlands	1989–2009	10,025	NR	76.0%	ΛH	≥21	1\2	Quartiles	3 years	Surgery	44
2018         USA         2004-2013         2445         62.0         90.6%         HV         3.1-15.8         0.1-1.0         Tertise         11 years           2013         Engand         2004-2018         54.03         NR         71.9%         HV         280         <20	Van de Poll-Fanse (5)	2011	Netherlands	1995-2006	638	66.0	76.5%	ΛH	15-20	-4	Tertiles	3 years	Surgery	NR
2013         England         2004-2008         5403         NR         71.9%         HV         280         Clouthlise         6 years           2013         Sweden         1987-2005         1335         66.00         74.0%         HV $\geq 7$ $\geq 6$ Cuthlise $\geq 7$ $\geq 7$ 2021         USA         2006-2013         11,739         65.06.30         85.1%         HV $\geq 7$ $\leq 6$ Cuthlise $\geq 7$	Yang (10)	2018	USA	2004-2013	2445	62.0	90.6%	ΛH	3.1-15.8	0.1 - 1.0	Tertiles	11 years	Surgery	450
2013         Sweden         1887-2005         1335         660         740%         HV $\geq 17$ $\leq 8$ Tertiles $\geq 4$ years           2021         USA         2006-2013         11/739         650-630         851%         HV         ><6	Coupland (11)	2013	England	2004-2008	5403	NR	71.9%	ΛH	≥80	<20	Quintiles	6 years	Surgery	NR
2021         USA         2006-2013         11739         62.06.5.0         85.1%         HV $56$ $56$ Dichotomies         5 years           2020         USA         2004-2016         37.665         NR         NR         HV $255$ $55$ $55$ $57$ $57$ years $5$ years           2009         USA         1994-199         2.246         NR $75.9\%$ HV $245$ $67.0$ $57.9\%$ $75.9\%$	Derogar (13)	2013	Sweden	1987-2005	1335	66.0	74.0%	ΛH	≥17	8	Tertiles	24 years	Surgery	NR
2020         USA         2004-2016         37,695         NR         NR         HV $\geq 25$ $\leq 5$ Quinties         5 years           2009         USA         1995-2004         2404         NR         75.9%         HV $\geq 5$ $< 2$ Quinties         5 years           2008         USA         1995-2004         2404         NR         75.9%         HV $> 5$ $< 2$ Quinties         5 years           2008         USA         1992-2002         822         NR         HV $> 12$ $< 2$ Quinties         5 years           2007         Sweden         1994-1997         1232         65.06.0         719%         HV $> 14$ $< 2$ Quinties         5 years           2007         Sweden         1994-1997         1167         NR         71%         HV $> 10$ $< 2$ Quinties         5 years           2011         Matralia         2011-2018         1167         NR         83.5%         HV $> 10$ $< 2$ Quinties         5 years           2011         Matralia         2011-2018         1167         NR         N	Patel (26)	2021	USA	2006-2013	11,739	62.0-63.0	85.1%	ΛH	>6	9≥	Dichotomies	5 years	Surgery	1018
2009         USA         195-2004         2404         NR         759%         HV $56$ $<2$ Quinties $5$ years           2008         USA         194-199         12.246         640-650         NR         HV         >15 $<2$ Quinties $6$ years           2008         USA         192-2002         822         NR         79.65         HV         >14 $<1$ Terties $5$ years           2007         USA         1997-1907         1199         65.0-66.0         71.9%         HV         >16         Terties $5$ years           2001         Sweden         1977-1905         1199         65.0-66.0         71.9%         HV         >10 $<$ Terties $17$ years           2010         Sweden         1947-1905         1167         NR         NR         HV         >10 $<$ $17$ years $17$ years           2011         Australia         2001-2005         316         NR         NR         NR $>$ $<$ $17 years         17 years           2011         Australia         2001-2005         316         NR         > $	Han (27)	2020	USA	2004-2016	37,695	NR	NR	ΛH	≥25	€5	Quintiles	5 years	Surgery	NR
2008         USA         1994-1990         12.46         64.0-65.0         NR         HV         >15 $< < < < < < < < < < < < < < < < < < < $	Gasper (28)	2009	USA	1995 - 2004	2404	NR	75.9%	ΛH	>6	$\Diamond$	Quintiles	5 years	Surgery	NR
2007 $USA$ $1992-2002$ $822$ $NR$ $796%$ $HV$ $>14$ $<4$ Tertles $5$ years $5$ years $2008$ $8weden$ $1994-1997$ $232$ $670$ $83.2%$ $HV$ $>10$ $0$ </td <td>Bilimoria (29)</td> <td>2008</td> <td>USA</td> <td>1994-1999</td> <td>12,246</td> <td>64.0-65.0</td> <td>NR</td> <td>ΗΛ</td> <td>&gt;15</td> <td>ΰ</td> <td>Quintiles</td> <td>6 years</td> <td>Surgery</td> <td>1154</td>	Bilimoria (29)	2008	USA	1994-1999	12,246	64.0-65.0	NR	ΗΛ	>15	ΰ	Quintiles	6 years	Surgery	1154
2008Sweden194-197232 $6.7.0$ $83.2\%$ $HV$ $\geq 10$ $6-9$ $Dichotomies$ $10$ years $10$ years2007Sweden1987-20001199 $650-660$ 71.9\% $HV$ $\geq 10$ $<10$ $Dichotomies$ $17$ years $17$ years2005Sweden1987-19061429 $660-670$ 7.8% $HV$ $\geq 16$ $C10$ $Dichotomies$ $17$ years2016Australia $2001-2015$ $1167$ $NR$ $NR$ $NR$ $HV$ $\geq 6$ $R$ $R$ $13$ years2017Australia $2001-2005$ $321$ $NR$ $8.5\%$ $HV$ $\geq 6$ $R$ $R$ $13$ years2010Australia $2001-2005$ $321$ $NR$ $8.5\%$ $HV$ $\geq 6$ $R$ $R$ $13$ years2011Australia $2001-2005$ $321$ $NR$ $8.5\%$ $HV$ $\geq 6$ $C$ $R$ $S$ 2012Mustralia $2001-2005$ $321$ $NR$ $8.5\%$ $HV$ $\geq 6$ $C$ $C$ $S$ $S$ 2013Natralia $200-2005$ $321$ $NR$ $R$ $R$ $P$ $C$ $C$ $Dichotomies$ $S$ years2014 $Iustralia200-20133578NRRRSCCDichotomiesIustralias2021Iustralia200-20133578NRNRHVSCCDichotomiesIustralias2021<$	Birkmeyer (30)	2007	USA	1992-2002	822	NR	79.6%	ΗΛ	>14	4	Tertiles	5 years	Surgery	206
2007Sweden1987-20001199650-66.071.9%HV $\geq 10$ $< 10$ Dichotomies17 years $< 17$ years2015Sweden1987-1996142966.0-67.07.8%HV $> 5$ $< 5$ Tertiles13 years $< 3$ years2021Australia2001-20151167NRNRNR $+ V$ $> 5$ $< 7$ $< 7$ $< 3$ years $< 3$ years2014Australia2001-2005908NR $80.5\%$ $+ V$ $> 66$ $< 76$ $0$ $< 9$ years $< 9$ 2017Australia2001-2005321NR $80.5\%$ $+ V$ $> 20$ $< 20$ $0$ $0$ $< 9$ years2017Australia2001-2005321NR $80.5\%$ $+ V$ $> 20$ $< 20$ $0$ $0$ $< 9$ years2017Japan2002-20133578NR $81.9\%$ $+ V$ $> 20$ $< 20$ $0$ $0$ $< 9$ years2017Japan206-20133578NR $NR$ $NR$ $+ V$ $> 20$ $< 20$ $0$ $0$ $< 9$ 2017Japan206-20133578NR $NR$ $NR$ $+ V$ $> 20$ $< 20$ $0$ $0$ $0$ 2017Japan194-19982961NR $NR$ $+ V$ $> 20$ $< 20$ $0$ $0$ $0$ 2018 $109$ $109$ $100$ $100$ $100$ $100$ $100$ $100$ $100$ $100$ $100$ <td>Sundelof (31)</td> <td>2008</td> <td>Sweden</td> <td>1994-1997</td> <td>232</td> <td>67.0</td> <td>83.2%</td> <td>ΗΛ</td> <td>≥10</td> <td>6-9</td> <td>Dichotomies</td> <td>10 years</td> <td>Surgery</td> <td>33</td>	Sundelof (31)	2008	Sweden	1994-1997	232	67.0	83.2%	ΗΛ	≥10	6-9	Dichotomies	10 years	Surgery	33
2005Sweden1987-19961429 $66.0-67.0$ $72.8\%$ HV>15 $< < < < < < < < < < < < < < < < < < < $	Rouvelas (32)	2007	Sweden	1987 - 2000	1199	65.0-66.0	71.9%	Η	≥10	<10	Dichotomies	17 years	Surgery	53
2021         Australia         2001-2015         1167         NR         NR         HV $\geq 6$ NR $5 \text{ years}$ 2014         Australia         2001-2008         908         NR         80.5%         HV $\geq 6$ Dichotomies $5 \text{ years}$ 2010         Australia         2000-2005         321         NR         80.5%         HV $\geq 0$ $\leq 6$ Dichotomies $9 \text{ years}$ 2010         Australia         2000-2005         321         NR $69.1\%$ HV $\geq 0$ $\leq 6$ Dichotomies $9 \text{ years}$ 2010         Australia         1994-2002         213         NR $69.1\%$ HV $\geq 20$ $\leq 0$ Dichotomies $9 \text{ years}$ 2011         Japan         1994-1998         213         NR $RV$ $8-70$ $\leq 10$ $10 \text{ years}$ $10 \text{ years}$ 2002         Japan         1994-1998         2961         NR         RV $54-70$ $\leq 10$ Tertiles $3 \text{ years}$ 2002         Japan         1994-1998         281         NR         NR	Wenner (33)	2005	Sweden	1987-1996	1429	66.0-67.0	72.8%	Η	>15	€5	Tertiles	13 years	Surgery	74
2014         Australia         2001-2008         908         NR         80.5%         HV         >6 $\leq$ $\leq$ Dichotomies         9 years           2010         Australia         2000-2005         321         NR         74.0%         HV         >20 $\leq$ Dichotomies         9 years           2010         Australia         2000-2005         321         NR         74.0%         HV         >20 $\leq$ Dichotomies         9 years           2007         Netherlands         1994-2002         213         NR         69.1%         HV         >20 $<$ Dichotomies         9 years           2007         Japan         1994-1998         213         NR         69.1%         HV $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$	Narendra (34)	2021	Australia	2001-2015	1167	NR	NR	ΛH	≥6	NR	Dichotomies	5 years	Surgery	24
2010         Australia         2000-2005         321         NR         74.0%         HV         >20 $\leq 10$ Tertiles         3 years         3           2007         Netherlands         1994-2002         213         NR         69.1%         HV $\geq 20$ $\leq 0$ Dichotomies         10 years         10 years           2007         Japan         2066-2013         3578         NR         69.1%         HV $\geq 20$ $\geq 0$ Dichotomies         10 years         10 years           2007         Japan         1994-1998         2961         NR         NR         HV $\leq 4-70$ $\leq 10$ Tertiles         10 years         10 years           2007         Japan         1994-1998         2961         NR         NR         HV $\leq 4-70$ $\leq 10$ Tertiles         10 years           2002         England         1994-1998         781         NR         HV $\leq 4-70$ $\leq 10$ Tertiles         5 years           2002         England         1994-1998         781         NR         HV $\geq 22$ Dichotomies         5 years           2014         Korea         200-201	Smith (35)	2014	Australia	2001-2008	908	NR	80.5%	ΛH	>6	9≥	Dichotomies	9 years	Surgery	42
	Stavrou (36)	2010	Australia	2000-2005	321	NR	74.0%	ΛH	>20	≤10	Tertiles	3 years	Surgery	NR
	Verhoef (37)	2007	Netherlands	1994 - 2002	213	NR	69.1%	ΛH	≥20	<20	Dichotomies	10 years	Surgery	18
2007         Japan         1994-1998         2961         NR         NR         HV         >43         <8         Quartiles         5 years           2002         England         1996-1997         781         NR         NR         HV         60-83         7-32         Tertiles         5 years           2014         China         2008-2011         2151         55.2         94.1%         HV         >222         Dichotomies         3 years           2014         China         2004-2017         11,346         64.2         92.6%         HV         >248         <12	Taniyama (38)	2021	Japan	2006-2013	3578	NR	83.5%	ΗV	54-70	≤10	Tertiles	10 years	Surgery	96
2002         England         1996-1997         781         NR         NR         HV         60-83         7-32         Tertiles         3 years           2014         China         2008-2011         2151         55.2         94.1%         HV         >22         Dichotomies         3 years           2014         China         2008-2011         2151         55.2         94.1%         HV         >22         Dichotomies         3 years           2021         Kora         2004-2017         11,346         64.2         92.6%         HV         >48         <12	Ioka (39)	2007	Japan	1994-1998	2961	NR	NR	HV	>43	8>	Quartiles	5 years	Surgery	143
2014         China         2008-2011         2151         55.2         94.1%         HV         >22         Dichotomies         3 years           2021         Korea         2004-2017         11,346         64.2         92.6%         HV         >48         <12	Bachmann (40)	2002	England	1996-1997	781	NR	NR	ΗV	60-83	7–32	Tertiles	3 years	Surgery	23
2021         Korea         2004-2017         11,346         64.2         92.6%         HV         ≥48         <12         Tertiles         5 years           2020         Brazil         2000-2013         1347         NR         84.9%         HV         >8         <5	Hsu (41)	2014	China	2008-2011	2151	55.2	94.1%	ΛH	>22	≤22	Dichotomies	3 years	Surgery	58
2020         Brazil         2000–2013         1347         NR         84.9%         HV         >8         <5         Dichotomies         5 years           2004         Conda         1000 2000         6.0         6.0         NP         HV         >8         <5	Kim (42)	2021	Korea	2004-2017	11,346	64.2	92.6%	ΛH	≥48	<12	Tertiles	5 years	Surgery	122
2004 Consider 1000 2000 420 42.0 ND HV >44 27 Outstilder 10 reason	Duarte (43)	2020	Brazil	2000-2013	1347	NR	84.9%	HV	-8	<5	Dichotomies	5 years	Surgery	NR
2000 Canada 1990-2000 029 03:0-03:0 NK 11V 244 2/ Quartues 10 years	Simunovic (44)	2006	Canada	1990 - 2000	629	63.0-65.0	NR	ΗV	≥44	<	Quartiles	10 years	Surgery	68

TABLE 1 Basic characteristics of all included studies for meta-analysis on the relation between hospital volume and outcome of esophagectomies for cancer.

Frontiers in Surgery

#### 3.2. Quality assessment

The quality of the included studies was assessed using the Newcastle-Ottawa Scale. The median Newcastle-Ottawa Scale score of the included studies was 7, with a range of 6–9 (Table 2).

# 3.3. Long-term os in relation to hospital volume

A total of 24 studies was included to assess the impact of highvolume vs. low-volume hospitals on long-term overall survival after esophagectomy. Regarding to the longest period of follow-ups, highvolume hospitals showed significantly better overall survival than lowvolume hospitals (HR: 0.77; 95% CI: 0.71–0.84, P < 0.01) (Figure 2).

Next, we analyzed the pooled HRs of OS (high-volume hospital vs. low-volume hospital) for multiple cutoff values (**Table 3**). Consistent results were found that high-volume hospitals showed a significant improvement in OS after esophagectomy than their low-volume counterparts (all  $P \le 0.05$ ).

#### 3.4. Subgroup analysis

Subgroup analysis was conducted based on volume grouping category in Figure 2. A significant improvement in OS after

esophagectomy was observed in high-volume hospitals as compared to that in their low-volume counterparts in each volume grouping category. The pooled HRs were 0.76 (95% CI: 0.71–0.81) for quintiles, 0.72 (95% CI: 0.61–0.85) for quartiles, 0.77 (95% CI:0.62–0.96) for tertiles, and 0.82 (95% CI:0.78–0.87) for dichotomies, respectively (Figure 2, Table 4).

In addition, we carried out subgroup analyses in relation to sample size, study country, year of publication, follow-up or study quality. Overall, the results were robust and that patients with esophagectomy significantly benefited from high-volume hospitals than from low-volume hospitals (Table 3).

#### 3.5. Sensitivity analyses

Sensitivity analyses with the leave-one-out method further revealed the consistent results, which were observed a significant improvement in OS after esophagectomy in high-volume hospitals as compared to that in their low-volume counterparts, with HRs ranging from 0.75 (95% CI: 0.68–0.83) to 0.79 (95% CI: 0.73–0.85) (Table 5).

## 3.6. Publication bias

We further assessed the publication bias (Figure 3). Because of the relatively small number of included studies in some volume

Study		Sele	ction		Comparability		Outcome		Total score
		Ш	III	IV	V	VI	VII	VIII	
Dikken 2012 (29)		*	*	*	**	*	*	*	8
Van de Poll-Fanse 2011 (30)	*	*	*		**	*	*	*	8
Yang 2019 (21)	*	*	*		*	*	*	*	7
Coupland 2013 (14)	*	*	*	*	**	*	*	*	9
Derogar 2013 (15)	*	*	*	*	**	*	*	*	9
Patel 2022 (6)	*	*	*		**	*	*	*	8
Han 2021 (7)	*	*	*	*	**	*	*	*	9
Gasper 2009 (8)	*	*	*	*	**	*	*	*	9
Bilimoria 2008 (22)	*	*	*	*	**	*	*	*	9
Birkmeyer 2007 (23)	*	*	*	*	**	*	*	*	9
Sundelof 2008 (24)			*	*	**	*	*	*	7
Rouvelas 2007 (9)			*	*	**	*	*		6
Wenner 2005 (25)		*	*	*	**		*		6
Narendra 2021 (26)		*	*	*	*	*	*		6
Smith 2014 (27)		*	*	*	**	*	*	*	8
Stavrou 2010 (28)			*	*	**	*	*	*	7
Verhoef 2007 (31)	*	*	*	*	**	*	*		8
Taniyama 2021 (32)	*	*		*	**	*	*		7
Ioka 2007 (33)			*	*	**		*	*	6
Bachmann 2002 (34)	*	*	*	*	*	*	*	*	8
Hsu 2014 (35)			*	*	**	*	*	*	7
Kim 2021 (36)	*	*	*	*	*	*	*		7
Duarte 2020 (37)		*	*	*	*	*	*		6
Simunovic 2006 (38)		*	*	*	*	*	*		6

 TABLE 2 Quality assessment of all included studies by Newcastle-Ottawa scale.

\*One score. I, representativeness of the exposed cohorts; II, selection of the non-exposed cohorts; III, ascertainment of exposure; IV, demonstration that outcome of interest was not present at start of study of interest; V, comparability of cohorts on the basis of the design or analysis; VI, assessment of outcomes; VII, was follow-up long enough for outcomes to occur; VIII, adequacy of follow-up of cohorts.

Study ID	Favors Higher volume hospitals	Favors Lower volume hospitals	HR (95% CI)	Weight %
Quintiles	_			
Bilimoria 2008			0.75 (0.69, 0.81)	5.51
Coupland 2013			0.82 (0.72, 0.95)	5.01
Gasper 2009	• •		0.61 (0.37, 0.99)	1.93
Han 2020			0.75 (0.64, 0.88)	
Subgroup, DL ( $I^2 = 0$	0.0%, p = 0.562)		0.76 (0.71, 0.81)	17.25
Quartiles	1			
Dikken 2012			0.77 (0.70, 0.85)	
Loka 2007			0.63 (0.53, 0.71)	4.93
Simunovic 2006			0.83 (0.63, 1.25)	2.94
Subgroup, DL ( $I^2 = 6$	64.3%, p = 0.061)		0.72 (0.61, 0.85)	13.26
Tertiles			4 04 (0 00 4 05)	5 74
Bachmann 2002			1.01 (0.96, 1.05)	
Birkmeyer 2007 Derogar 2013			0.71 (0.54, 0.92) 0.94 (0.80, 1.10)	3.66 4.80
Kim 2021			0.52 (0.45, 0.59)	
Stavrou 2010			<ul> <li>1.52 (0.43, 0.39)</li> <li>1.52 (0.57, 4.00)</li> </ul>	
Taniyama 2021	i	•	0.64 (0.54, 0.75)	4.74
van de Poll-Franse	2011	_	0.80 (0.60, 1.07)	
Wenner 2005			0.91 (0.73, 1.14)	
Yang 2018			0.63 (0.49, 0.81)	3.81
Subgroup, DL ( $l^2 = 9$	93.2%, p = 0.000)		0.77 (0.62, 0.96)	35.96
Dichotomies				
Duarte 2020			0.82 (0.71, 0.94)	4.99
Hsu 2014			0.73 (0.58, 0.92)	4.03
Narendra 2021		-	0.88 (0.74, 1.06)	4.58
Patel 2021	- <b>+</b> +-		0.81 (0.74, 0.89)	
Rouvelas 2007	_i-◆-	ł	0.90 (0.79, 1.04)	
Smith 2014			0.78 (0.67, 0.91)	
Sundelof 2008	+		0.77 (0.53, 1.00)	
Verhoef 2007	•	-	0.62 (0.34, 1.12)	1.47
Subgroup, DL ( $I^2 = 0$	0.0%, p = 0.684)		0.82 (0.78, 0.87)	33.54
Heterogeneity betwee $Overall$ , DL ( $I^2 = 86$ .)	een groups: p = 0.233 4%, p = 0.000)		0.77 (0.71, 0.84)	100.00
		1	1	
	.25	1	4	

grouping category meta-analyses, we consider that publication bias should exist.

## 4. Discussion

This meta-analysis outlined the most up-to-date evidence on the relationship between hospital volume and long-term survival outcomes in esophagectomy. We found for the first time that centralization of esophagectomy in high-volume hospitals improved OS as compared to that in low-volume hospitals and patients with esophageal cancer will benefit from an esophagectomy conducted in a higher volume hospital than in a lower one, whether in total or in volume grouping category. However, we were still unable to decide the optimal cutoff value of dividing high- and low-volume hospitals in current study.

Centralization of esophageal cancer surgery has been common in the Netherlands, England, and Canada (18, 39, 40), Comparing a

TABLE 3 Comparisons of the overall survivals between high- and low-volume hospitals by different cutoff values of hospital volume.

Cutoff values of	No. of	No. of	Effect estimate			
hospital volume (CV) HVH (≥CV) vs. LVH ( <cv)< td=""><td>studies</td><td>patients</td><td>HR</td><td>(95% Cl)</td><td><i>P</i> value</td></cv)<>	studies	patients	HR	(95% Cl)	<i>P</i> value	
5	6	55,152	0.76	0.71-0.80	< 0.001	
6	11	80,408	0.79	0.75-0.84	< 0.001	
7	8	66,606	0.79	0.73-0.85	< 0.001	
8	9	67,261	0.79	0.74-0.84	< 0.001	
9	10	68,596	0.78	0.74-0.83	< 0.001	
10	12	74,347	0.77	0.72-0.83	< 0.001	
11	11	73,148	0.77	0.72-0.83	< 0.001	
12-14	12	84,494	0.75	0.68-0.83	< 0.001	
15	11	83,672	0.75	0.68-0.84	< 0.001	
16	9	80,741	0.72	0.65-0.80	< 0.001	
17	8	68,494	0.72	0.63-0.81	< 0.001	
18-19	7	67,159	0.71	0.61-0.82	< 0.001	
20	9	77,976	0.71	0.63-0.81	< 0.001	
21	8	71,427	0.72	0.63-0.82	< 0.001	
22	7	63,232	0.64	0.56-0.73	< 0.001	
23-25	6	61,081	0.70	0.60-0.82	< 0.001	
26-32	5	23,386	0.69	0.57-0.84	< 0.001	
33-43	6	24,167	0.75	0.59-0.95	0.02	
44	5	21,737	0.74	0.55-1.00	0.05	

CI, confidence interval; HR, hazard ratio; HVH, high-volume hospital; LVH, low-volume hospital; No., number.

TABLE 4 Subgroup analyses of comparisons of the overall survivals between high- and low-volume hospitals.

Subgroup	No. of	No. of	Effect estimate				
HVH vs. LVH	studies	patients	HR (95% CI)	P value			
Total	24	113,014	0.77 (0.71-0.84)	< 0.001			
Volume group							
Dichotomies	8	18,956	0.82 (0.78-0.87)	< 0.001			
Tertiles	9	22,695	0.77 (0.62-0.96)	0.02			
Quartiles	3	13,615	0.72 (0.61-0.85)	< 0.001			
Quintiles	4	57,748	0.76 (0.71-0.81)	< 0.001			
Sample size							
>5,000	6	88,454	0.73 (0.65-0.82)	< 0.001			
<5,000	18	24,560	0.79 (0.72-0.87)	< 0.001			
Study country							
Western countries	20	98,381	0.82 (0.76-0.88)	< 0.001			
Eastern countries	4	20,036	0.61 (0.53-0.70)	< 0.001			
Year of publication							
2002-2012	13	33,900	0.80 (0.70-0.90)	< 0.001			
2013-2022	11	79,114	0.75 (0.67-0.83)	< 0.001			
Follow-up							
Longest follow-up ≥10 years	8	11,060	0.79 (0.69-0.91)	< 0.001			
Longest follow-up <10 years	16	101,954	0.76 (0.69-0.85)	< 0.001			
Study quality							
High	19	107,243	0.74 (0.67-0.83)	< 0.001			
Moderate	5	5771	0.87 (0.80-0.94)	< 0.001			

CI, confidence interval; HR, hazard ratio; HVH, high-volume hospital; LVH, low-volume hospital; No., number.

centralized country (England) with a non-centralized country (U.S.), a previous study of 13,291 patients illustrated a lower inhospital mortality in England hospitals than those in the U.S. (4.2% vs. 5.5%) (41). Regarding this, centralization is urgently

TABLE 5 Sensitivity	analysis using	leave-one-out	method	for	overall
survival of high-volu	me hospitals v	s. low-volume ho	ospitals.		

Given named study is omitted	Hazard ratio	95% CI	P value
Dikken (29)	0.77	0.70-0.84	< 0.001
Van de Poll-Fanse (30)	0.77	0.71-0.84	< 0.001
Yang (21)	0.78	0.71-0.85	< 0.001
Coupland (14)	0.77	0.70-0.84	< 0.001
Derogar (15)	0.76	0.70-0.83	< 0.001
Patel (6)	0.77	0.70-0.84	< 0.001
Han (7)	0.77	0.71-0.84	< 0.001
Gasper (8)	0.75	0.68-0.83	< 0.001
Bilimoria (22)	0.77	0.70-0.85	< 0.001
Birkmeyer (23)	0.77	0.71-0.84	< 0.001
Sundelof (24)	0.77	0.70-0.84	< 0.001
Rouvelas (9)	0.76	0.70-0.84	< 0.001
Wenner (25)	0.77	0.70-0.84	< 0.001
Narendra (26)	0.77	0.70-0.84	< 0.001
Smith (27)	0.77	0.70-0.84	< 0.001
Stavrou (28)	0.77	0.70-0.84	< 0.001
Verhoef (31)	0.77	0.71-0.84	< 0.001
Taniyama (32)	0.78	0.71-0.85	0.02
Ioka (33)	0.78	0.72-0.85	0.05
Bachmann (34)	0.76	0.71-0.81	< 0.001
Hsu (35)	0.77	0.71-0.84	< 0.001
Kim (36)	0.79	0.73-0.85	< 0.001
Duarte (37)	0.77	0.70-0.84	< 0.001
Simunovic (38)	0.77	0.70-0.84	<0.001

CI, confidence interval.

required, in terms of high-volume hospitals with sufficient surgical volumes, skillful interdisciplinary teams, to provide the optimal treatment for patients with esophageal cancer.

Although the reasons why high-volume hospitals are associated with better long-term survival are still not fully understood, highvolume hospitals may provide patients with better multidisciplinary teams, more comprehensive preoperative examinations, more accurate preoperative diagnosis, perioperative management, and high-quality surgical care, more specialized surgeons who have more consistent skills of performing curable operations for esophageal cancer patients (42-45). Compared with low-volume hospitals, high-volume hospitals not only have a lower complication rate after esophagectomies, but also the ability of managing complications (46). In addition, the applications of neoadjuvant chemoradiation, perioperative chemotherapy, and postoperatively follow-up can improve long-term outcomes after esophagectomies; therefore, highvolume hospitals are more likely to provide a better overall cancer therapy and care, and the size of hospital volume may serve as a significant indicator of the overall medical quality and health care (47).

Unfortunately, it is difficult for patients to know the overall quality of nearby hospitals. Based on the main findings of current study, patients can select relatively higher volume hospitals nearby. Considering the importance of such knowledges, policy makers should make efforts to educate people for selecting the optimal hospitals for the treatments of specific diseases (e.g., esophagectomy for esophageal cancer), through public reporting systems.

Our study still has limitations. First, this study has the potential for selection bias of individual studies because of



the original data, even with case mix adjustment. Second, all the included studies were observational and retrospective. Third, some of the included studies used the same database (e.g., Sweden), and some participants might be overlapped, even though the study period were different; however, sensitivity analyses of a leave-one-out method confirmed that all the current results were robust. Fourth, as some of the data in the included studies were obtained from the National Cancer Registry, some details of the surgery, such as surgical approach and the extent of lymph nodes dissection, were unknown. Fifth, the volume grouping categories of the annual hospital volumes across the included studies varied greatly, and there was still no optimal threshold, and the main findings of current study thus need to be verified in further studies.

# 5. Conclusion

In summary, high-volume hospitals significantly improved long-term OS of patients with esophageal cancer after esophagectomy as compared to their low-volume counterparts. Esophagectomy should be centralized in highvolume hospitals.

## Data availability statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

## Author contributions

Conceptualization: QW, CDZ. Methodology: QW, SN. Software: QW. Validation: QW, MN, TF, SN, CDZ, SM. Formal analysis: QW, CDZ. Investigation: QW, MN, TF, SN, CDZ, SM. Resources: QW, CDZ. Data curation: QW, CDZ. Writing—original draft preparation: QW. Writing—review and editing: MN, SM. Visualization: QW. Supervision: SM. Reading and approving the final manuscript: QW, MN, TF, SN, CDZ, SM. All authors contributed to the article and approved the submitted version.

## Acknowledgments

The authors thank the members of the Department of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, for their thoughtful discussion and helpful advice. The authors also thank all participants and study authors in this study. QW was partly supported by the Japan China Sasakawa Medical Fellowship. CDZ was partly supported by the China Scholarship Council (201908050148).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

## References

1. Sheetz KH, Dimick JB, Nathan H. Centralization of high-risk cancer surgery within existing hospital systems. *J Clin Oncol.* (2019) 37(34):3234–42. doi: 10.1200/ JCO.18.02035

2. Balzano G, Guarneri G, Pecorelli N, Paiella S, Rancoita PMV, Bassi C, et al. Modelling centralization of pancreatic surgery in a nationwide analysis. *Br J Surg.* (2020) 107(11):1510–9. doi: 10.1002/bjs.11716

3. van Putten M, Nelen SD, Lemmens VEPP, Stoot JHMB, Hartgrink HH, Gisbertz SS, et al. Overall survival before and after centralization of gastric cancer surgery in The Netherlands. *Br J Surg.* (2018) 105(13):1807–15. doi: 10.1002/bjs.10931

4. Asplund J, Mattsson F, Plecka-Ostlund M, Markar SR, Lagergren J. Annual surgeon and hospital volume of gastrectomy and gastric adenocarcinoma survival in a population-based cohort study. *Acta Oncol.* (2022) 61(4):425–32. doi: 10.1080/0284186X.2022.2025612

5. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. (2013) 63(4):232-48. doi: 10.3322/caac.21185

6. Patel DC, Jeffrey Yang CF, He H, Liou DZ, Backhus LM, Lui NS, et al. Influence of facility volume on long-term survival of patients undergoing esophagectomy for esophageal cancer. *J Thorac Cardiovasc Surg.* (2022) 163(4):1536–1546 e1533. doi: 10.1016/j.jtcvs.2021.05.048

7. Han S, Kolb JM, Hosokawa P, Friedman C, Fox C, Scott FI, et al. The volumeoutcome effect calls for centralization of care in esophageal adenocarcinoma: results from a large national cancer registry. *Am J Gastroenterol.* (2021) 116(4):811–5. doi: 10.14309/ajg.000000000001046

8. Gasper WJ, Glidden DV, Jin C, Way LW, Patti MG. Has recognition of the relationship between mortality rates and hospital volume for major cancer surgery in California made a difference?: a follow-up analysis of another decade. *Ann Surg.* (2009) 250(3):472–83. doi: 10.1097/SLA.0b013e3181b47c79

9. Rouvelas I, Lindblad M, Zeng W, Viklund P, Ye W, Lagergren J. Impact of hospital volume on long-term survival after esophageal cancer surgery. *Arch Surg.* (2007) 142(2):113–7; discussion 118. doi: 10.1001/archsurg.142.2.113

10. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. *JAMA Surg.* (2021) 156(8):721–9. doi: 10.1001/jamasurg.2021.2373

11. Yu S, Zhang W, Ni W, Xiao Z, Wang Q, Zhou Z, et al. A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. *Radiother Oncol.* (2019) 140:159–66. doi: 10. 1016/j.radonc.2019.06.020

12. He S, Xu J, Liu X, Zhen Y. Advances and challenges in the treatment of esophageal cancer. *Acta Pharm Sin B.* (2021) 11(11):3379–92. doi: 10.1016/j.apsb. 2021.03.008

13. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. *Lancet*. (2017) 390(10110):2383–96. doi: 10.1016/S0140-6736(17)31462-9

14. Coupland VH, Lagergren J, Luchtenborg M, Jack RH, Allum W, Holmberg L, et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008. *Gut.* (2013) 62 (7):961–6. doi: 10.1136/gutjnl-2012-303008

15. Derogar M, Sadr-Azodi O, Johar A, Lagergren P, Lagergren J. Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. *J Clin Oncol.* (2013) 31(5):551–7. doi: 10.1200/JCO.2012.46. 1517

16. Gillison E. W., Powell J., McConkey C. C., Spychal R. T. Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. *Br J Surg*. (2002) 89(3):344–8. doi: 10.1046/j.0007-1323.2001.02015.x

17. Wang Q, Nasu M, Fukunaga T, Nojiri S, Zhang C-D, Mine S. Association of hospital volume and long-term survival after esophagectomy: a systematic review and meta-analysis. *INPLASY*. (2022). doi: 10.37766/inplasy2022.7.0023

18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Br Med J.* (2021) 372:n71. doi: 10.1136/bmj.n71

19. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25 (9):603–5. doi: 10.1007/s10654-010-9491-z

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

20. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in metaanalyses. Br Med J. (2003) 327(7414):557-60. doi: 10.1136/bmj.327.7414.557

21. Yang GQ, Mhaskar R, Rishi A, Naghavi AO, Frakes JM, Almhanna K, et al. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy. *Dis Esophagus*. (2019) 32(8):doy124. doi: 10.1093/dote/doy124

22. Bilimoria KY, Bentrem DJ, Feinglass JM, Stewart AK, Winchester DP, Talamonti MS, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. *J Clin Oncol.* (2008) 26(28):4626–33. doi: 10.1200/JCO.2007.15.6356

23. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. *Ann Surg.* (2007) 245(5):777–83. doi: 10.1097/01.sla. 0000252402.33814.dd

24. Sundelof M, Lagergren J, Ye W. Surgical factors influencing outcomes in patients resected for cancer of the esophagus or gastric cardia. *World J Surg.* (2008) 32 (11):2357–65. doi: 10.1007/s00268-008-9698-2

25. Wenner J, Zilling T, Bladström A, Alvegård T. The influence of surgical volume on hospital mortality and 5-year survival for carcinoma of the oesophagus and gastric cardia. *Anticancer Res.* (2005) 25(1B):419–24.

26. Narendra A, Baade PD, Aitken JF, Fawcett J, Leggett B, Leggett C, et al. Hospital characteristics associated with better "quality of surgery" and survival following oesophagogastric cancer surgery in Queensland: a population-level study. *ANZ J Surg.* (2021) 91(3):323–8. doi: 10.1111/ans.16397

27. Smith RC, Creighton N, Lord RV, Merrett ND, Keogh GW, Liauw WS, et al. Survival, mortality and morbidity outcomes after oesophagogastric cancer surgery in New South Wales, 2001-2008. *Med J Aust.* (2014) 200(7):408–13. doi: 10.5694/mja13.11182

28. Stavrou EP, Smith GS, Baker DF. Surgical outcomes associated with oesophagectomy in New South Wales: an investigation of hospital volume. *J Gastrointest Surg.* (2010) 14(6):951-7. doi: 10.1007/s11605-010-1198-7

29. Dikken JL, Dassen AE, Lemmens VE, Putter H, Krijnen P, van der Geest L, et al. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in The Netherlands between 1989 and 2009. *Eur J Cancer.* (2012) 48(7):1004–13. doi: 10.1016/j.ejca.2012.02.064

30. van de Poll-Franse LV, Lemmens VE, Roukema JA, Coebergh JW, Nieuwenhuijzen GA. Impact of concentration of oesophageal and gastric cardia cancer surgery on long-term population-based survival. *Br J Surg.* (2011) 98 (7):956–63. doi: 10.1002/bjs.7493

31. Verhoef C, van de Weyer R, Schaapveld M, Bastiaannet E, Plukker JT. Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists. *Ann Surg Oncol.* (2007) 14 (5):1678-87. doi: 10.1245/s10434-006-9333-0

32. Taniyama Y, Tabuchi T, Ohno Y, Morishima T, Okawa S, Koyama S, et al. Hospital surgical volume and 3-year mortality in severe prognosis cancers: a population-based study using cancer registry data. *J Epidemiol.* (2021) 31(1):52–8. doi: 10.2188/jea.JE20190242

33. Ioka A, Tsukuma H, Ajiki W, Oshima A. Hospital procedure volume and survival of cancer patients in Osaka, Japan: a population-based study with latest cases. Jpn J Clin Oncol. (2007) 37(7):544–53. doi: 10.1093/jjco/hym052

34. Bachmann M, Alderson D, Edwards D, Wotton S, Bedford C, Peters T, et al. Cohort study in south and west England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. *Br J Surg.* (2002) 89(7):914–22. doi: 10.1046/j.1365-2168.2002.02135.x

35. Hsu PK, Chen HS, Wu SC, Wang BY, Liu CY, Shih CH, et al. Impact of hospital volume on long-term survival after resection for oesophageal cancer: a populationbased study in taiwandagger. *Eur J Cardiothorac Surg.* (2014) 46(6):e127–135; discussion e135. doi: 10.1093/ejcts/ezu377

36. Kim BR, Jang EJ, Jo J, Lee H, Jang DY, Ryu HG. The association between hospital case-volume and postoperative outcomes after esophageal cancer surgery: a population-based retrospective cohort study. *Thorac Cancer.* (2021) 12(18):2487–93. doi: 10.1111/1759-7714.14096

37. Duarte MBO, Pereira EB, Lopes LR, Andreollo NA, Carvalheira JBC. Chemoradiotherapy with or without surgery for esophageal squamous cancer according to hospital volume. *JCO Glob Oncol.* (2020) 6:828–36. doi: 10.1200/JGO. 19.00360

38. Simunovic M, Rempel E, Thériault M, Coates A, Whelan T, Holowaty E, et al. Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. *Can J Surg.* (2006) 49(4):251–8.

39. Varghese TK Jr., Wood DE, Farjah F, Oelschlager BK, Symons RG, MacLeod KE, et al. Variation in esophagectomy outcomes in hospitals meeting leapfrog volume outcome standards. *Ann Thorac Surg.* (2011) 91(4):1003–9; discussion 1009–1010. doi: 10.1016/j.athoracsur.2010.11.006

40. Chang AC. Centralizing esophagectomy to improve outcomes and enhance clinical research: invited expert review. *Ann Thorac Surg.* (2018) 106(3):916–23. doi: 10.1016/j.athoracsur.2018.04.004

41. Munasinghe A, Markar SR, Mamidanna R, Darzi AW, Faiz OD, Hanna GB, et al. Is it time to centralize high-risk cancer care in the United States? Comparison of outcomes of esophagectomy between England and the United States. *Ann Surg.* (2015) 262(1):79–85. doi: 10.1097/SLA.00000000000805

42. Van den Broeck T, Oprea-Lager D, Moris L, Kailavasan M, Briers E, Cornford P, et al. A systematic review of the impact of surgeon and hospital caseload volume on oncological and nononcological outcomes after radical prostatectomy for

nonmetastatic prostate cancer. Eur Urol. (2021) 80(5):531-45. doi: 10.1016/j.eururo. 2021.04.028

43. Khanna A, Saarela O, Lawson K, Finelli A, Haber GP, Lee B, et al. Hospital quality metrics for radical cystectomy: disease specific and correlated to mortality outcomes. J Urol. (2019) 202(3):490-7. doi: 10.1097/JU.00000000000282

44. Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, et al. Association of hospital volume and quality of care with survival for ovarian cancer. *Obstet Gynecol.* (2017) 130(3):545–53. doi: 10.1097/AOG.00000000002164

45. Ghaferi AA, Birkmeyer JD, Dimick JB. Complications, failure to rescue, and mortality with major inpatient surgery in medicare patients. *Ann Surg.* (2009) 250 (6):1029–34. doi: 10.1097/sla.0b013e3181bef697

46. Ghaferi A, Birkmeyer J, Dimick J. Hospital volume and failure to rescue with high-risk surgery. *Med Care.* (2011) 49(12):1076–81. doi: 10.1097/MLR. 0b013e3182329b97

47. Eskander A, Irish J, Groome PA, Freeman J, Gullane P, Gilbert R, et al. Volumeoutcome relationships for head and neck cancer surgery in a universal health care system. *Laryngoscope*. (2014) 124(9):2081–8. doi: 10.1002/lary.24704